Core Viewpoint - The announcement from Jiet Bio (688026.SH) regarding a share reduction plan by its shareholder, Guangzhou Luogang District Huizi Investment Management Partnership, indicates a planned reduction of up to 186,315 shares, representing no more than 0.1327% of the company's total share capital, due to the shareholder's personal funding needs [1][2]. Group 1: Shareholder Reduction Plan - The shareholder, Huizi Investment, plans to reduce its holdings through centralized bidding from July 2, 2025, to October 1, 2025 [1][2]. - The total shares held by Huizi Investment before the reduction is 1,396,950 shares, which accounts for 1.00% of the company's total share capital [2]. - The shares intended for reduction were acquired before the IPO and through capital reserve conversion [2]. Group 2: Company Background - Jiet Bio was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 22, 2020, with an issuance of 25 million shares at a price of 16.49 yuan per share [3]. - The company raised a total of 412.25 million yuan from its initial public offering, with a net amount of 379.41 million yuan after deducting issuance costs [3][5]. - The company has conducted two fundraising activities, totaling 852.25 million yuan [5]. Group 3: Financial Information - The company issued convertible bonds approved by the China Securities Regulatory Commission, raising a total of 440 million yuan, with a net amount of approximately 432.49 million yuan after expenses [4]. - The company distributed cash dividends of 0.6 yuan per share and increased its capital stock by 0.4 shares per share based on a total share capital of 100 million shares prior to the distribution [6].

Core Viewpoint - The announcement details a share reduction plan by a major shareholder of Guangzhou Jiete Biological Filtration Co., Ltd., indicating a planned sale of shares due to personal financial needs, while ensuring that this action will not affect the company's control or governance structure [2][3][7]. Group 1: Shareholder Information - The shareholder, Guangzhou Luogang District Huizi Investment Management Partnership (Limited Partnership), holds 1,396,950 shares, representing 1.00% of the company's total equity [2]. - The shares were acquired prior to the company's IPO and became tradable on January 30, 2023, after the lifting of restrictions [2]. Group 2: Reduction Plan Details - The shareholder plans to reduce their holdings by up to 186,315 shares, which is approximately 0.1327% of the total equity, within a three-month period starting from July 2, 2025, to October 1, 2025 [3]. - The reduction will be executed through centralized bidding, and any changes in the company's share structure during this period will lead to adjustments in the reduction plan [3]. Group 3: Control and Governance Impact - The reduction plan will not lead to a change in the company's control, as the shareholder is an associated party of the controlling shareholder, ensuring that governance and operational continuity remain unaffected [3][7]. - The actual controller's family member, Wang Jing, will not reduce her indirect holdings through the investment partnership, further stabilizing the control structure [3][7]. Group 4: Previous Commitments - The shareholder has previously committed not to transfer or manage shares held prior to the IPO for a period of 12 months post-listing, which aligns with the current reduction plan [5][6]. - Wang Jing has also made commitments regarding the management of her shares, including restrictions on transfer during specific periods [6].

本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司 证券代码：688026 证券简称：洁特生物 公告编号：2025-033 重要内容提示： ? 股东持有的基本情况 本次减持计划实施前，股东广州萝岗区汇资投资管理合伙企业（有限合伙） （以下简称"汇资投资"）持有广州洁特生物过滤股份有限公司（以下简称"公司"） 股份 1,396,950 股，占公司总股本 1.00%。上述股份来源为公司 IPO 前取得的及 通过资本公积转增股本取得的股份，已于 2023 年 1 月 30 日解除限售并上市流通。 ? 减持计划的主要内容 因股东自身资金需求，汇资投资拟于减持计划披露之日起 15 个交易日后的 份数量不超过 186,315 股，减持比例不超过公司总股本的 0.1327%。若公司在上 述减持计划实施期间发生送股、转增股本、增发新股股份变动事项，则上述减持 计划将作出相应调整。 汇资投资普通合伙人、执行事务合伙人王婧为公司实际控制人 Yuan Ye Jam ...

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-033 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持有的基本情况 本次减持计划实施前，股东广州萝岗区汇资投资管理合伙企业（有限合伙） （以下简称"汇资投资"）持有广州洁特生物过滤股份有限公司（以下简称"公司"） 股份 1,396,950 股，占公司总股本 1.00%。上述股份来源为公司 IPO 前取得的及 通过资本公积转增股本取得的股份，已于 2023 年 1 月 30 日解除限售并上市流通。 减持计划的主要内容 因股东自身资金需求，汇资投资拟于减持计划披露之日起 15 个交易日后的 3 个月内（即 2025 年 7 月 2 日至 2025 年 10 月 1 日）通过集中竞价方式减持股 份数量不超过 186,315 股，减持比例不超过公司总股本的 0.132 ...

洁特生物公告，因股东自身资金需求，汇资投资拟于2025年7月2日至2025年10月1日期间，通过集中竞 价方式减持不超过18.63万股，占公司总股本的0.1327%。 ...

Core Viewpoint - The company has reached a settlement in a legal dispute involving its wholly-owned subsidiary, which will positively impact its financial position by recovering a significant amount of previously written-off bad debts [2][11]. Summary by Sections Legal Proceedings Overview - The lawsuit involves Guangzhou Jiete Biological Filtration Co., Ltd.'s subsidiary, Guangzhou Baifeier Air Purification Materials Co., Ltd., as the plaintiff in a contract dispute with Shandong Dayong New Materials Co., Ltd. [2][4]. - The total amount involved in the case is approximately 10,866,391.80 yuan, excluding additional costs [3]. Settlement Agreement - A settlement agreement was reached where Shandong Dayong will pay 6,470,000 yuan to Baifeier, covering all related costs and fees [11]. - The agreement stipulates that both parties will not pursue any further claims against each other regarding this dispute [11][12]. Financial Impact - The company had previously made provisions for bad debts amounting to 7,533,582.08 yuan related to this case, which will now be reversed following the settlement [12]. - The company also recorded a provision for inventory depreciation of 3,208,618.86 yuan for PTFE composite mask non-woven fabric [12]. Future Actions - Following the receipt of the settlement amount, the company will apply to withdraw its legal claims and terminate the execution of the contract dispute [11][12].

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-032 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于子公司诉讼事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次诉讼的基本情况 公司全资子公司拜费尔与山东大荣分别于 2020 年 3 月 13 日、2020 年 4 月 6 日、2020 年 4 月 14 日签订了三份关于 PTFE 复合口罩无纺布的《销售合同》（以 下合称"《销售合同》"），2021 年拜费尔就《销售合同》纠纷一案向法院提 起诉讼，具体内容详见公司于 2021 年 7 月 16 日披露的《关于子公司提起诉讼的 1 1、 案件所处的诉讼阶段：和解结案 2、 上市公司所处的当事人地位：广州洁特生物过滤股份有限公司（以下简称 "公司"）全资子公司广州拜费尔空气净化材料有限公司（以下简称"拜 费尔"）为（2024）粤民申 2817 号案件再审申请人（一审原告， ...

Core Viewpoint - Jiet Bio (688026) reported a stable stock price of 15.08 CNY as of May 23, 2025, with no change from the previous week, indicating a steady market position [1] Company Announcements - Jiet Bio plans to utilize up to 300 million CNY of temporarily idle raised funds for cash management, aiming to enhance the efficiency of fund usage without affecting ongoing projects [1] - The company’s board approved two key resolutions: 1. Use up to 250 million CNY of idle self-owned funds to purchase high-safety, liquid investment products for a duration of 12 months, with funds being recyclable [1] 2. Use up to 300 million CNY of temporarily idle raised funds for similar investment purposes, ensuring the funds are returned to the special account for raised funds after the investment period [1] - The total amount raised by the company was 440 million CNY, with a net amount of approximately 432.49 million CNY after related expenses [1] - Independent directors and the sponsor, Minsheng Securities Co., Ltd., expressed agreement with the cash management plan, emphasizing compliance with legal regulations and company policies [1]

民生证券股份有限公司 关于广州洁特生物过滤股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 民生证券股份有限公司（以下简称"民生证券"、"保荐机构"）作为广州洁 特生物过滤股份有限公司（以下简称"洁特生物"、"公司"）2022 年向不特定对 象发行可转换公司债券并在科创板上市的保荐机构，根据《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》《上海证券交易所科创板股票 上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等有关法律法规和规范性文件的要求，民生证券对洁特生物使用部分暂时闲置募 集资金进行现金管理事项进行了核查，发表如下核查意见： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意广州洁特生物过滤股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2022〕432 号）同意注 册，公司向不特定对象共计发行 440.00 万张，每张面值为人民币 100 元，按面 值发行。本次发行的募集资金总额为 440,000,000.00 元，扣除未付的承销及保荐 费 5,700,000.00 元后实际收到的金额为 434,300,000 ...

广州洁特生物过滤股份有限公司独立董事 关于第四届董事会第二十次会议相关事项的独立意见 一、关于使用部分暂时闲置募集资金进行现金管理的独立意见 公司本次使用暂时闲置募集资金不超过 3 亿元进行现金管理，董事会审议 的表决程序合法、有效，符合公司当前的实际情况，有利于提高公司资金的使用 效率，获得一定的投资收益，符合《上市公司监管指引第 2 号——上市公司募集 资金管理使用的监管要求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律、法规以及规范性文件和公司章程、公司募集资金使用 管理制度的相关规定，不存在变相改变募集资金投向和损害股东利益的情况。同 意公司使用暂时闲置募集资金不超过 3 亿元进行现金管理。 根据中国证监会《上市公司独立董事管理办法》《上海证券交易所科创板股 票上市规则》及《公司章程》等有关规定，我们作为广州洁特生物过滤股份有限 公司（以下简称"公司"）独立董事，本着对公司、全体股东负责的态度，基于 独立、客观、审慎的原则，现就公司关于第四届董事会第二十次会议相关事项发 表如下独立意见： 广州洁特生物过滤股份有限公司 独立董事：洪炜、刘佳、陈锦棋 2025 年 5 月 22 ...